Allakos Inc. (ALLK): Price and Financial Metrics
ALLK Price/Volume Stats
| Current price | $1.07 | 52-week high | $5.64 |
| Prev. close | $1.06 | 52-week low | $1.00 |
| Day low | $1.03 | Volume | 160,419 |
| Day high | $1.12 | Avg. volume | 1,312,727 |
| 50-day MA | $1.30 | Dividend yield | N/A |
| 200-day MA | $2.41 | Market Cap | 93.59M |
ALLK Stock Price Chart Interactive Chart >
Allakos Inc. (ALLK) Company Bio
Allakos Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutic antibodies targeting allergic, inflammatory, and proliferative diseases. The company is developing AK002 for the treatment of eosinophilic gastritis and eosinophilic gastroenteritis, urticaria, indolent systemic mastocytosis, and severe allergic conjunctivitis. The company was founded in 2012 and is based in San Carlos, California.
Latest ALLK News From Around the Web
Below are the latest news stories about ALLAKOS INC that investors may wish to consider to help them evaluate ALLK as an investment opportunity.
Allakos Inc (ALLK) Reports Increased R&D Expenses and Net Loss in Q3 2023Financial Highlights and Business Updates from Allakos's Latest Earnings Filing |
Allakos Provides Business Update and Reports Third Quarter 2023 Financial ResultsSAN CARLOS, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today provided a business update and reported financial results for the third quarter ended September 30, 2023. Recent Allakos Events Completed enrollment in both the Phase 2 study of subcutaneous lirentelimab in patients with atopic dermatitis and the Phase 2b study of subcutaneous |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on ThursdayIt's time to start the day with a breakdown of the biggest pre-market stock movers worth keeping tabs on for Thursday morning! |
Following a 63% decline over last year, recent gains may please Allakos Inc. (NASDAQ:ALLK) institutional ownersKey Insights Given the large stake in the stock by institutions, Allakos' stock price might be vulnerable to their... |
Why Shares of Allakos Are Up WednesdayShares of clinical-stage biotech company Allakos (NASDAQ: ALLK) were up more than 15% as of 11:40 a.m. on Wednesday. Despite the rise, Allakos' stock is still down more than 70% so far this year. Allakos focuses on monoclonal antibodies to trigger responses in the body's immune cells to treat various conditions, including allergies, and inflammatory and proliferative diseases. |
ALLK Price Returns
| 1-mo | -14.40% |
| 3-mo | -7.76% |
| 6-mo | -41.21% |
| 1-year | -74.88% |
| 3-year | -89.83% |
| 5-year | -71.58% |
| YTD | -60.81% |
| 2023 | -67.58% |
| 2022 | -13.99% |
| 2021 | -30.07% |
| 2020 | 46.81% |
| 2019 | 82.44% |
Loading social stream, please wait...